250
Participants
Start Date
November 3, 2019
Primary Completion Date
April 30, 2027
Study Completion Date
October 31, 2029
Ifinatamab deruxtecan (I-DXd)
A total anti-B7H3 antibody and MAAA-1181a
WITHDRAWN
Columbia University Medical Center, New York
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
WITHDRAWN
Sidney Kimmel Cancer Center - Thomas Jefferson, Philadelphia
WITHDRAWN
Florida Cancer Specialists, Orlando
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Tennessee Oncology, Nashville
WITHDRAWN
The Ohio State University, Columbus
RECRUITING
Henry Ford Hospital, Detroit
RECRUITING
Washington University, St Louis
RECRUITING
MDACC (MD Anderson Cancer Center), Houston
RECRUITING
Sarah Cannon Research Institute at HealthONE, Denver
WITHDRAWN
Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute, Los Angeles
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RECRUITING
Aichi Cancer Center Hospital, Aichi
RECRUITING
National Cancer Center Hospital East, Chiba
RECRUITING
Hokkaido University Hospital, Hokkaido
RECRUITING
Osaka University Hospital, Osaka
RECRUITING
Kindai University Hospital, Ōsaka-sayama
RECRUITING
Saitama Cancer Center, Saitama
RECRUITING
Shizuoka Cancer Center Hospital and Research Institute, Shizuoka
RECRUITING
National Cancer Center Hospital, Tokyo
RECRUITING
Cancer Institute Hospital of JFCR, Tokyo
RECRUITING
Showa University Hospital, Tokyo
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Daiichi Sankyo
INDUSTRY